[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655227":3},{"organization":4,"outcomesModule":7,"designInfo":48,"detailedDescription":11,"studyPopulation":11,"armGroups":58,"interventions":95,"overallOfficials":11,"centralContacts":104,"locations":110,"responsibleParty":129,"collaborators":11,"id":131,"slug":132,"hasResults":133,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":11,"eligibilityCriteria":137,"healthyVolunteers":133,"sex":138,"minAge":139,"maxAge":140,"enrollmentInfo":141,"targetDuration":11,"studyType":144,"phases":145,"briefSummary":147,"conditions":148,"keywords":11,"overallStatus":150,"whyStopped":11,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":160},{"fullName":5,"class":6},"Innovent Biologics (Suzhou) Co. Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":27,"otherOutcomes":11},[9,13,16,19,22,24],{"measure":10,"description":11,"timeFrame":12},"Number of participants with Adverse Event",null,"up to Day 169 for SAD;up to Day 225 for MAD",{"measure":14,"description":15,"timeFrame":12},"Change in systolic blood pressure after dosing in each dose group(Unit of Measure: mmHg)","Systolic blood pressure will be measured and recorded at each specified time point",{"measure":17,"description":18,"timeFrame":12},"Change in diastolic blood pressure after dosing in each dose group(Unit of Measure: mmHg)","diastolic blood pressure will be measured and recorded at each specified time point",{"measure":20,"description":21,"timeFrame":12},"Number of participants with clinically significant abnormal findings in complete physical examination(Unit of Measure: participants)","A complete physical examination will be performed at each specified time point, including assessment of general appearance, respiratory system, cardiovascular system, abdomen, skin, head and neck (including ears, nose, and throat), lymph nodes, thyroid gland, musculoskeletal system (including spine and extremities), and neurological system. Any finding that is new or worsened from baseline and deemed clinically significant by the investigator will be",{"measure":23,"description":11,"timeFrame":12},"Number of participants with clinically significant changes in physical examination results；",{"measure":25,"description":26,"timeFrame":12},"Number of participants with abnormal ECG changes before and after administration in each dose group","Abnormal changes in ECG heart rate, rhythm, and morphology of each wave segment will be recorded.",[28,31,34,36,38,40,42,44,46],{"measure":29,"description":11,"timeFrame":30},"renal clearance (CLr)","up to Day 3 for SAD;up to Day 57 for MAD",{"measure":32,"description":33,"timeFrame":12},"Immunogenicity characteristics of IBI3046","To characterize the immunogenicity of IBI3046 based on serum sample analysis at prespecified time points as defined in the study protocol.",{"measure":35,"description":11,"timeFrame":12},"Pharmacodynamics (PD) Body weight: change from baseline in body weight. baseline in body weight.",{"measure":37,"description":11,"timeFrame":30},"Area Under the Curve (AUC) of the serum concentration-time profile",{"measure":39,"description":11,"timeFrame":30},"Maximum Concentration (Cmax) of the drug in serum",{"measure":41,"description":11,"timeFrame":30},"time to maximum concentration (Tmax)",{"measure":43,"description":11,"timeFrame":30},"Elimination Half-life (t1\u002F2)",{"measure":45,"description":11,"timeFrame":30},"Amount of drug excreted in urine (Ae)",{"measure":47,"description":11,"timeFrame":30},"Fraction of dose excreted in urine(Fe)",{"allocation":49,"interventionModel":50,"interventionModelDescription":11,"primaryPurpose":51,"observationalModel":11,"timePerspective":11,"maskingInfo":52},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":53,"maskingDescription":11,"whoMasked":54},"TRIPLE",[55,56,57],"PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR",[59,65,71,75,79,83,87,91],{"label":60,"type":61,"description":62,"interventionNames":63},"Part1-SAD Placebo Control Group","PLACEBO_COMPARATOR","Subjects receive single-dose matching placebo for IBI3046 in Part1 SAD phase, across 5 corresponding cohorts.",[64],"Drug: placebo",{"label":66,"type":67,"description":68,"interventionNames":69},"Part3-Combination Background Drug + IBI3046 Group","EXPERIMENTAL","All subjects receive active reference drug first, followed by administration of IBI3046 across 2 different dose cohorts, to evaluate safety, tolerability, PK and PD.",[70],"Drug: IBI3046",{"label":72,"type":61,"description":73,"interventionNames":74},"Part4-Combination: Continuous Reference Drug with Intermittent Placebo Control Group","All subjects receive continuous active reference drug. Matching placebo for IBI3046 is administered at corresponding time points across 2 cohorts in Part4 combination phase.",[64],{"label":76,"type":67,"description":77,"interventionNames":78},"Part4-Combination: Continuous Reference Drug with Intermittent IBI3046 Treatment Group","All subjects receive continuous active reference drug. IBI3046 is administered at different time points across 2 different dose cohorts, to evaluate safety, tolerability, PK and PD.",[70],{"label":80,"type":61,"description":81,"interventionNames":82},"Part3-Combination: Reference Drug followed by Placebo Control Group","All subjects receive active reference drug first, followed by matching placebo for IBI3046 across 2 corresponding cohorts in Part3 combination phase.",[64],{"label":84,"type":61,"description":85,"interventionNames":86},"Part2-MAD Placebo Control Group","Subjects receive matching placebo for IBI3046 in Part2 MAD phase, across 3 corresponding cohorts.",[64],{"label":88,"type":67,"description":89,"interventionNames":90},"Part2-MAD IBI3046 Treatment Group","Subjects receive multiple ascending repeated doses of IBI3046 across 3 different dose cohorts, to evaluate safety, tolerability and steady-state pharmacokinetics.",[70],{"label":92,"type":67,"description":93,"interventionNames":94},"Part1-SAD IBI3046 Treatment Group","Subjects receive single ascending doses of IBI3046 across 5 different dose cohorts, to evaluate safety, tolerability and pharmacokinetics.",[70],[96,101],{"type":97,"name":98,"description":99,"armGroupLabels":100,"otherNames":11},"DRUG","IBI3046","subcutaneous injection",[92,88,66,76],{"type":97,"name":102,"description":99,"armGroupLabels":103,"otherNames":11},"placebo",[60,84,80,72],[105],{"name":106,"role":107,"phone":108,"phoneExt":11,"email":109},"baiyi yan","CONTACT","17710042669","baiyi.yan@innoventbio.com",[111],{"facility":112,"status":11,"city":113,"state":114,"zip":115,"country":116,"countryCode":117,"cosmosGeoPoint":118,"geoPoint":123,"contacts":124},"Beijing Friendship Hospital, Capital Medical University","Beijing","Beijing Municipality","101125","China","CN",{"type":119,"coordinates":120},"Point",[121,122],116.39723,39.9075,{"lat":122,"lon":121},[125],{"name":126,"role":107,"phone":127,"phoneExt":11,"email":128},"Ruihua Dong","010-80839386","ruihua_dong_rw@163.com",{"type":130,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100655227","phase-1-a-study-of-ibi3046-in-participants-with-overweight-or-obesity-100655227",false,"NCT07809945","A Study of IBI3046 in Participants With Overweight or Obesity","A Randomized, Double Blind, Placebo Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of IBI3046 in Chinese Participants With Overweight or Obesity","Inclusion Criteria:\n\n* 1.Aged between 18 and 65 years (inclusive) at the time of informed consent, male or female;\n* 2.At screening, 24 kg\u002Fm² ≤ BMI ≤ 40 kg\u002Fm²;\n* 3.Body weight change ≤ 5 % within 3 months prior to screening ;\n* 4.Female participants of child bearing potential and male participants whose partners are of child bearing potential must agree to use highly effective contraceptive methods during the study and for 6 months after the last study drug administration. For female participants of child bearing potential, the pregnancy test result must be negative at screening. Female participants shall not breast feed. Male \u002F female participants must be willing to refrain from sperm \u002F oocyte donation during the study and for 6 months after the last study drug administration;\n* 5.Able to understand study procedures and requirements, willing to strictly comply with the clinical trial protocol, and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Secondary overweight or obesity caused by drugs, genetic or other systemic diseases.\n* 2\\. Abnormal glucose metabolism, including diabetes history or clinically significant abnormal glycemic indicators at screening.\n* 3\\. Clinically significant abnormal liver function, hematological parameters, ECG indicators or vital signs at screening.\n* 4\\. Positive screening results for infectious pathogen markers.\n* 5\\. Personal or family history of specific thyroid neoplasms or endocrine disorders, or clinically significant abnormal thyroid function and thyroid lesions at screening.\n* 6\\. History of pancreatitis, severe lipid metabolism disorders, severe hypoglycemia or diabetic ketoacidosis.\n* 7\\. Presence of untreated or clinically significant systemic organ diseases, mental disorders or suicidal risk.\n* 8\\. History of malignant tumors (excluding partial skin cancers) within 5 years.\n* 9\\. Positive screening results for infectious pathogen markers.\n* 10\\. Personal or family history of specific thyroid neoplasms or endocrine disorders, or clinically significant abnormal thyroid function and thyroid lesions at screening.\n* 11\\. History of pancreatitis, severe lipid metabolism disorders, severe hypoglycemia or diabetic ketoacidosis.\n* 12\\. Presence of untreated or clinically significant systemic organ diseases, mental disorders or suicidal risk.\n* 13\\. History of malignant tumors (excluding partial skin cancers) within 5 years.","ALL","18 Years","65 Years",{"count":142,"type":143},128,"ESTIMATED","INTERVENTIONAL",[146],"PHASE1","This study evaluates the safety, tolerability, pharmacokinetics and pharmacodynamics of IBI3046 in Chinese overweight or obese participants, comprising four phases: single ascending dose (SAD), multiple ascending dose (MAD), IBI3046 administration after mazdutide discontinuation, and IBI3046 in combination with mazdutide",[149],"Obesity and Overweight","NOT_YET_RECRUITING","2026-09-03",{"date":153,"type":154},"2026-09-09","ACTUAL",{"date":156,"type":143},"2026-09-15",{"date":158,"type":143},"2028-10-09",{"name":5,"class":6},1]